Analyst firms · Morgan Stanley · TAK
Morgan Stanley TAK price target and rating history
Takeda Pharmaceutical Company Limited (TAK) · Health Care
Morgan Stanley rates Takeda Pharmaceutical Company Limited (TAK) Overweight, as of its latest action on Jan 13, 2026. It has published 3 rating actions on TAK since October 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Overweight
- Price target
- Not stated
- Median target, all firms
- Too few
- Actions on TAK
- 3
Every Morgan Stanley rating on TAK
- Jan 13, 2026
- Apr 2, 2025
- Oct 7, 2021
How other firms rate TAK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Bernstein | Outperform | Apr 8, 2026 | |
| Morgan Stanley | Overweight | Jan 13, 2026 |
Questions about Morgan Stanley and TAK
- What is Morgan Stanley's rating on TAK?
- Morgan Stanley rates TAK Overweight, a bullish rating, as of Jan 13, 2026.
- When did Morgan Stanley last change its view on TAK?
- On Jan 13, 2026, Morgan Stanley resumes coverage at Overweight.
All Morgan Stanley ratingsTAK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.